pirenzepine has been researched along with Hallucinations in 23 studies
Pirenzepine: An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
Hallucinations: Subjectively experienced sensations in the absence of an appropriate stimulus, but which are regarded by the individual as real. They may be of organic origin or associated with MENTAL DISORDERS.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Olanzapine (Zyprexa) is an atypical neuroleptic used in adult and pediatric patients for the management of schizophrenia." | 5.31 | Diabetic ketoacidosis associated with olanzapine in an adolescent patient. ( Scott, SM; Selva, KA, 2001) |
| "The aim of the study was to investigate patterns of the P600 component of event-related potentials (ERPs) elicited during a working memory test in 16 male schizophrenic patients experiencing auditory hallucinations before and after treatment with clozapine and olanzapine, and 13 male normal subjects matched for age and educational level." | 5.10 | Do atypical antipsychotics fail to exert cognitive sparing effects? ( Christodoulou, GN; Matsopoulos, GK; Oulis, P; Papageorgiou, C; Rabavilas, A; Uzunoglu, N; Vasios, C, 2003) |
| "To compare olanzapine and clozapine for safety and efficacy measures of psychosis and motor function in patients with PD and chronic hallucinations." | 5.09 | Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. ( Blasucci, LM; Goetz, CG; Leurgans, S; Pappert, EJ, 2000) |
| " This article compares the effects of olanzapine and placebo in the emergence of hallucinations or delusions in AD patients with symptoms of agitation/aggression but little or no psychotic symptomatology at baseline." | 5.09 | The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease. ( Breier, A; Clark, WS; Feldman, PD; Street, JS, 2001) |
| "Psychosis was assessed with the Neuropsychiatric Inventory/Nursing Home (NPI-NH) version and the Brief Psychiatric Rating Scale (BPRS)." | 2.70 | Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies. ( Clark, WS; Cummings, JL; Masterman, D; Street, J, 2002) |
| "Olanzapine is a novel atypical antipsychotic drug with few reported extrapyramidal side effects which may be more suitable for controlling hallucinosis in these patients." | 2.69 | Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. ( Ford, KS; Graham, JM; Sagar, HJ; Sussman, JD, 1998) |
| "Four patients affected by severe Parkinson's disease developed leucopenia (900-1200 WBC) during treatment of psychosis (3) or untreatable insomnia (1) with clozapine (37." | 1.31 | Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine. ( Bonanni, L; Gambi, F; Iacono, D; Onofrj, M; Thomas, A, 2000) |
| "Olanzapine (Zyprexa) is an atypical neuroleptic used in adult and pediatric patients for the management of schizophrenia." | 1.31 | Diabetic ketoacidosis associated with olanzapine in an adolescent patient. ( Scott, SM; Selva, KA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (30.43) | 18.2507 |
| 2000's | 16 (69.57) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Friedman, JH | 1 |
| Fernandez, HH | 1 |
| Ondo, WG | 1 |
| Levy, JK | 1 |
| Vuong, KD | 1 |
| Hunter, C | 1 |
| Jankovic, J | 1 |
| Livingston, M | 1 |
| Livingston, H | 1 |
| Papageorgiou, C | 1 |
| Oulis, P | 1 |
| Vasios, C | 1 |
| Matsopoulos, GK | 1 |
| Uzunoglu, N | 1 |
| Rabavilas, A | 1 |
| Christodoulou, GN | 1 |
| Teaktong, T | 1 |
| Piggott, MA | 1 |
| Mckeith, IG | 2 |
| Perry, RH | 1 |
| Ballard, CG | 1 |
| Perry, EK | 1 |
| O'Brien, J | 1 |
| Barber, R | 1 |
| Graham, JM | 1 |
| Sussman, JD | 1 |
| Ford, KS | 1 |
| Sagar, HJ | 1 |
| Walker, Z | 1 |
| Grace, J | 1 |
| Overshot, R | 1 |
| Satarasinghe, S | 1 |
| Swan, A | 1 |
| Katona, CL | 1 |
| Gardner, DM | 1 |
| Milliken, J | 1 |
| Dursun, SM | 1 |
| Rudolf, J | 1 |
| Ghaemi, M | 1 |
| Schmülling, S | 1 |
| Snoddgrass, PL | 1 |
| Labbate, LA | 1 |
| Granger, AS | 1 |
| Hanger, HC | 1 |
| Solhkhah, R | 1 |
| Finkel, J | 1 |
| Hird, S | 1 |
| Goetz, CG | 1 |
| Blasucci, LM | 1 |
| Leurgans, S | 1 |
| Pappert, EJ | 1 |
| Onofrj, M | 1 |
| Thomas, A | 1 |
| Bonanni, L | 1 |
| Iacono, D | 1 |
| Gambi, F | 1 |
| Clark, WS | 2 |
| Street, JS | 1 |
| Feldman, PD | 1 |
| Breier, A | 1 |
| Selva, KA | 1 |
| Scott, SM | 1 |
| Sa, DS | 2 |
| Lang, AE | 2 |
| Edell, WS | 1 |
| Tunis, SL | 1 |
| Leucht, S | 1 |
| Cummings, JL | 1 |
| Street, J | 1 |
| Masterman, D | 1 |
| Reeves, RR | 1 |
| Torres, RA | 1 |
| Liberto, V | 1 |
| Hart, RH | 1 |
2 reviews available for pirenzepine and Hallucinations
| Article | Year |
|---|---|
Atypical antipsychotics in Parkinson-sensitive populations.
Topics: Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Clozapine; Dementia, Vascular; Dibenzothia | 2002 |
Using antipsychotics in elderly patients.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Delusions; Hallucinations; Humans; Olanzapine; Pirenzep | 2002 |
6 trials available for pirenzepine and Hallucinations
| Article | Year |
|---|---|
Olanzapine treatment for dopaminergic-induced hallucinations.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Dopamine Agonists; Double-Blind Me | 2002 |
Do atypical antipsychotics fail to exert cognitive sparing effects?
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain; Clozapine; Cognition; Double-Blind Method; Evok | 2003 |
Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note.
Topics: Aged; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Dose-Response Relationship, Dru | 1998 |
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.
Topics: Aged; Behavior; Benzodiazepines; Clozapine; Double-Blind Method; Female; Hallucinations; Humans; Mal | 2000 |
The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Delus | 2001 |
Efficacy of olanzapine in the treatment of psychosis in dementia with lewy bodies.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Behavior; Benzodiazepines; Cognition; Delusions; Dose | 2002 |
15 other studies available for pirenzepine and Hallucinations
| Article | Year |
|---|---|
Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Autoradiography; Binding, Competitive; Case-Control S | 2005 |
Marked improvement in tardive dyskinesia following treatment with olanzapine in an elderly subject.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Dyskinesia, Drug-Induced; Hallucinations; Humans; Male; | 1998 |
Olanzapine in dementia with Lewy bodies: a clinical study.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Contraindicatio | 1999 |
Olanzapine overdose.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Overdose; Female; Hallucinations; Humans; Olanzap | 1999 |
Deterioration of parkinsonian symptoms following treatment of dopaminergic hallucinosis with olanzapine.
Topics: Aged; Antiparkinson Agents; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine | 1999 |
Tardive dyskinesia from risperidone and olanzapine in an alcoholic man.
Topics: Alcoholism; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 1; Dyskinesia, Drug-Induc | 1999 |
Olanzapine: extrapyramidal side effects in the elderly.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Extrapyramidal Tracts; Female; Hallu | 1999 |
Possible risperidone-induced visual hallucinations.
Topics: Adolescent; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Diagnosis, Du | 2000 |
Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal. Clinical case descriptions with commentary on switch-over to olanzapine.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Benzodiazepines; Clozapine; Dose-Response Relationshi | 2000 |
Diabetic ketoacidosis associated with olanzapine in an adolescent patient.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Diabetic Ketoacidosis; Female; Hallucinations; Hu | 2001 |
Olanzapine for psychosis in Parkinson's disease.
Topics: Benzodiazepines; Hallucinations; Humans; Olanzapine; Parkinson Disease; Pirenzepine | 2001 |
Antipsychotic treatment of behavioral and psychological symptoms of dementia in geropsychiatric inpatients.
Topics: Aged; Aged, 80 and over; Aggression; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Depre | 2001 |
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.
Topics: Aged; Antipsychotic Agents; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; Hallucinations; Hu | 2001 |
Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients.
Topics: Antipsychotic Agents; Benzodiazepines; Bias; Clozapine; Hallucinations; Humans; Olanzapine; Parkinso | 2001 |
Atypical neuroleptic malignant syndrome associated with olanzapine.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Cell Count; Hallucinations; Humans; Male; Middle Aged; | 2002 |